DDrare: Database of Drug Development for Rare Diseases

Searched query = "Hereditary pancreatitis", "Chronic pancreatitis"
The queries were searched in Public_title, Scientific_title, and Condition. Export date: 03/15/2021. Trials are sorted by Date_enrollment from most recent to oldest in the table.

Drug = 98% dehydrated alcohol; A04AD10; ACETYLCYSTEINE; ANTOX; ANTOX (vers) 1.2; ANTOX (vers.)1.2; ASCORBIC ACID; Acetate; Acetyl-L-carnitine; Acetyl-L-carnitine 1000mg 2X per day for 3 months; Acetylcysteine; Alanine; Alcohol; Alpha 1-Antitrypsin; Alpha 1-antitrypsin; Amino acids; Amlodipine; Amlodipine (drug); Analgesics; Antioxidant plus Pregabalin; Antioxidants; Antox version 1.2; Ascorbic acid; Autologous mesenchymal stromal cell; Behavioral: smoking and alcohol assumption; Benzoyl-L-tyrosyl-[1-13C]alanine (Bz-Tyr-Ala); Bupivacaine; Bupivicaine alone; CREON; Calcium; Calcium, Dietary; Carbon; Carbon monoxide; Carnitine; Cholecalciferol; Creon; Creon 10000; Creon 25000; Creon36™; DRONABINOL; Device: Mayo Interactive Breath Hold Monitor; Diagnostic Test: Hemoglobin A1c; Diagnostic Test: Mixed Meal Tolerance Test; Diagnostic Test: Other exploratory blood biomarkers; Diagnostic Test: genetic sequencing; Diazepam; Dronabinol; ERCP with Bupivacaine infusion; EUR-1008 (APT-1008) High Dose; EUR-1008 (APT-1008) Low Dose; EUR-1066-A; EUR-1066-B; EUS procedure with drug injection; Ensure Surgical; Esomeprazole; Etanercept; FLUIMUCIL*20CPR EFF 600MG; Fluimucil; Gabapentin; Gabapentin prescriptions; Gold; Helopanflat Mono®; Hemoglobin; Human Secretin; Human secretin; Hydroxychloroquine; Indomethacin; Intra Plexus Triamcinolone and Bupivicaine Injection; Kreon 25000; L-Carnitine; LANREOTIDE ACETATE; LIPASE; Lannacher; Lanreotide; Liprotamase; Lyrica; Lyrica®; MAGNESIUM ASPARTATE HYDROCHLORIDE; METHIONINE; MONITOR; MS1819; MS1819-SD; Magnesiocard 2.5mmol; Magnesium; Magnesium aspartate; Methionine; Mezym F; Midazolam; Multienzymes (lipase, protease etc.); NI-03; Namisol; Nexium (esomeprazole magnesium); OXYCODONE; OXYCODONE HYDROCHLORIDE; Omeprazole; Other: Carbon monoxide-bubbled mediums; Other: EUS procedure; Other: Laboratory Biomarker Analysis; Other: Low-intensity exercise therapy; Other: No enzyme therapy; Other: Nutrition counseling; Other: Quality-of-Life Assessment; Other: Questionnaire Administration; Oxycodone; Oxycodone Depot ”Sandoz”, depot tablets; Oxycodonhydrochlorid ”Lannacher”, depot tablets; Oxynorm; PFD; PL 00512/0150; Pancreatic enzymes; Pancreatin; Pancrelipase; Pancrelipase Delayed Release Capsule; Pancrelipase delayed release capsule; Pancrelipase/Pancreas Powder; Panzytrat; Panzytrat 25.000; Panzytrat 25.000 FIP-E units of Lipase; Pentoxifylline; Perflubutane; Pioglitazone; Pregabalin; Procedure: Celiac Block with triamcinolone and bupivicaine; Procedure: No Celiac Block; Procedure: endoscopic drainage of the main pancreatic duct; Procedure: extracorporeal shock wave lithotripsy; Prolastin; Prolastin-C; Proton pump inhibitor (PPI); REGN475/SAR164877; RG1068 (Synthetic Human Secretin); RVG 13760; Radiation: UV-filtered light.; Radiation: UVB; Recombinant Microbial Lipase SLV339; Recombinant microbial lipase; Reparixin; S-Ketamin; S-ketamin; SA; SA-001; SELENIUM; SLV339; Secretin; Selenium; Simvastatin; Somatuline; Somatuline Autogel 90 mg; Soy bread; Synthetic human secretin; TOCOPHEROL; Tanezumab; Tetrahydro-6,6,9-tri methyl-3-penthyl-6 H-dibenzo[ b,d ]pyran-1-ol; Tetrahydrocannabinol; Thalidomide; Tocopherol; Triamcinolone; Tyr; VIOKASE 16; Viokase 16; Viokase 16 (pancrelipase) + Nexium; Viokase® 16; Vitamin D; Vitamin D 100ug; Vitamin D 10ug; Yarrowia lipolytica lipase; ZENTASE; Zenpep

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT02869893 (ClinicalTrials.gov)	August 10, 2016	5/6/2016	MRCP: A Reliable, Non Invasive Method for Staging Chronic Pancreatitis in Pediatrics	Magnetic Resonance Cholangiopancreatography (MRCP): A Reliable, Non Invasive Method for Staging Chronic Pancreatitis From Minimal Change Disease to the Advanced Stages in Pediatrics	Healthy Volunteers	Drug: Secretin	Children's Hospital Medical Center, Cincinnati	ChiRhoClin, Inc.;The National Pancreas Foundation	Completed	6 Years	15 Years	All	57	N/A	United States
2	NCT02458118 (ClinicalTrials.gov)	June 2012	27/5/2015	Pancreatic Perfusion Using Secretin and MRI	Study to Assess Pancreatic Blood Flow at Rest and During Stimulation Using Magnetic Resonance Imaging (fMRI) in Patients With Chronic Pancreatitis	Chronic Pancreatitis	Drug: Secretin	University of Nottingham	NULL	Recruiting	18 Years	80 Years	Both	15	Phase 1;Phase 2	United Kingdom
3	NCT01265875 (ClinicalTrials.gov)	December 2010	22/12/2010	Secretin Infusion for Pain Due to Chronic Pancreatitis	Secretin Infusion for Pain Due to Chronic Pancreatitis	Chronic Pancreatitis	Drug: Human Secretin	ChiRhoClin, Inc.	Dartmouth-Hitchcock Medical Center	Completed	18 Years	70 Years	All	12	Phase 1;Phase 2	United States
4	NCT01452217 (ClinicalTrials.gov)	September 2010	10/10/2011	Non-invasive MRI to Quantify the Effect of Secretin on Pancreatic Blood Flow and Perfusion in Healthy Volunteers	The Use of Non-invasive MRI to Quantify the Effect of Secretin on Pancreatic Blood Flow and Perfusion in Healthy Volunteers	Chronic Pancreatitis	Drug: Secretin	University of Nottingham	NULL	Completed	18 Years	75 Years	Male	12	Phase 1	United Kingdom
5	NCT00620919 (ClinicalTrials.gov)	February 2008	22/1/2008	Secretin Enhanced Multidetector CT Pancreatography for Evaluation of Known or Suspected Chronic Pancreatitis	RG1068 (Synthetic Human Secretin) Enhanced Multidetector CT Pancreatography: Evaluation of the Pancreatic Duct in Patients With Known or Suspected Chronic Pancreatitis	Chronic Pancreatitis	Drug: RG1068 (Synthetic Human Secretin)	Massachusetts General Hospital	NULL	Terminated	18 Years	90 Years	Both	0	Phase 1	United States
No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
6	NCT00621283 (ClinicalTrials.gov)	February 2008	22/1/2008	Secretin Enhanced MRCP for Evaluation of Pancreatic Duct in Pediatric Population	RG1068 (Synthetic Human Secretin) Enhanced MRCP for Morphological Evaluation of the Pancreatic Duct in the Pediatric Population	Acute Recurrent Pancreatitis;Chronic Pancreatitis	Drug: RG1068 (Synthetic Human Secretin)	Massachusetts General Hospital	NULL	Terminated	2 Years	18 Years	Both	0	Phase 1	United States

No.

TrialID

Date_
enrollment

Date_
registration

Public_title

Scientific_title

Condition

Intervention

Primary_
sponsor

Secondary_
sponsor

Recruitment_
Status

Inclusion_
agemin

Inclusion_
agemax

Inclusion_
gender

Target_
size

Phase

Countries

NCT02869893
(ClinicalTrials.gov)

August 10, 2016

5/6/2016

MRCP: A Reliable, Non Invasive Method for Staging Chronic Pancreatitis in Pediatrics

Magnetic Resonance Cholangiopancreatography (MRCP): A Reliable, Non Invasive Method for Staging Chronic Pancreatitis From Minimal Change Disease to the Advanced Stages in Pediatrics

Healthy Volunteers

Drug: Secretin

Children's Hospital Medical Center, Cincinnati

ChiRhoClin, Inc.;The National Pancreas Foundation

Completed

6 Years

15 Years

All

N/A

United States

NCT02458118
(ClinicalTrials.gov)

June 2012

27/5/2015

Pancreatic Perfusion Using Secretin and MRI

Study to Assess Pancreatic Blood Flow at Rest and During Stimulation Using Magnetic Resonance Imaging (fMRI) in Patients With Chronic Pancreatitis

Chronic Pancreatitis

Drug: Secretin

University of Nottingham

NULL

Recruiting

18 Years

80 Years

Both

Phase 1;Phase 2

United Kingdom

NCT01265875
(ClinicalTrials.gov)

December 2010

22/12/2010

Secretin Infusion for Pain Due to Chronic Pancreatitis

Chronic Pancreatitis

Drug: Human Secretin

ChiRhoClin, Inc.

Dartmouth-Hitchcock Medical Center

Completed

18 Years

70 Years

All

Phase 1;Phase 2

United States

NCT01452217
(ClinicalTrials.gov)

September 2010

10/10/2011

Non-invasive MRI to Quantify the Effect of Secretin on Pancreatic Blood Flow and Perfusion in Healthy Volunteers

The Use of Non-invasive MRI to Quantify the Effect of Secretin on Pancreatic Blood Flow and Perfusion in Healthy Volunteers

Chronic Pancreatitis

Drug: Secretin

University of Nottingham

NULL

Completed

18 Years

75 Years

Male

Phase 1

United Kingdom

NCT00620919
(ClinicalTrials.gov)

February 2008

22/1/2008

Secretin Enhanced Multidetector CT Pancreatography for Evaluation of Known or Suspected Chronic Pancreatitis

RG1068 (Synthetic Human Secretin) Enhanced Multidetector CT Pancreatography: Evaluation of the Pancreatic Duct in Patients With Known or Suspected Chronic Pancreatitis

Chronic Pancreatitis

Drug: RG1068 (Synthetic Human Secretin)

Massachusetts General Hospital

NULL

Terminated

18 Years

90 Years

Both

Phase 1

United States

No.

TrialID

Date_
enrollment

Date_
registration

Public_title

Scientific_title

Condition

Intervention

Primary_
sponsor

Secondary_
sponsor

Recruitment_
Status

Inclusion_
agemin

Inclusion_
agemax

Inclusion_
gender

Target_
size

Phase

Countries

NCT00621283
(ClinicalTrials.gov)

February 2008

22/1/2008

Secretin Enhanced MRCP for Evaluation of Pancreatic Duct in Pediatric Population

RG1068 (Synthetic Human Secretin) Enhanced MRCP for Morphological Evaluation of the Pancreatic Duct in the Pediatric Population

Acute Recurrent Pancreatitis;Chronic Pancreatitis

Drug: RG1068 (Synthetic Human Secretin)

Massachusetts General Hospital

NULL

Terminated

2 Years

18 Years

Both

Phase 1

United States